Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Taxes (2016 - 2020)

Myriad Genetics (MYGN) has disclosed Current Taxes for 7 consecutive years, with $6.1 million as the latest value for Q2 2020.

  • On a quarterly basis, Current Taxes rose 103.33% to $6.1 million in Q2 2020 year-over-year; TTM through Jun 2020 was $6.1 million, a 103.33% increase, with the full-year FY2020 number at $6.1 million, up 103.33% from a year prior.
  • Current Taxes was $6.1 million for Q2 2020 at Myriad Genetics, up from $3.5 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $9.8 million in Q3 2018 to a low of $2.3 million in Q1 2016.
  • A 5-year average of $4.6 million and a median of $3.6 million in 2019 define the central range for Current Taxes.
  • Peak YoY movement for Current Taxes: surged 168.75% in 2017, then plummeted 39.44% in 2018.
  • Myriad Genetics' Current Taxes stood at $3.0 million in 2016, then increased by 6.67% to $3.2 million in 2017, then skyrocketed by 53.12% to $4.9 million in 2018, then fell by 18.37% to $4.0 million in 2019, then soared by 52.5% to $6.1 million in 2020.
  • Per Business Quant, the three most recent readings for MYGN's Current Taxes are $6.1 million (Q2 2020), $3.5 million (Q1 2020), and $4.0 million (Q4 2019).